INmune Bio Analyst Price Targets - Benzinga

INmune Bio Inc

INMBNASDAQ

Trade with Public

Trade with Public

$1.52

0.096.29%

Últ. Act.: Oct 27, 6:37 PM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

INmune Bio Analyst Price Targets - Benzinga

INmune Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for INmune Bio (INMB).

Price Target Range — 5 Quarters

Analyst Consensus — 6 Analysts

5Buy

1Hold

Consensus RatingBuy# Analysts6Avg. Consensus PT$10Upside to Avg. PT+566.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Mar 11, 2026	LUCID CAPITAL MARKETS	Elemer Piros	Upgrade	Neutral→Buy	$2→$9
Aug 12, 2025	Freedom Broker	Ilya Zubkov	PT Cut	Buy	$7→$4
Jul 3, 2025	Freedom Broker	Ilya Zubkov	Initiate	Buy	$7
Jul 2, 2025	Maxim Group	Jason McCarthy	PT Cut	Buy	$30→$8
Jul 1, 2025	BTIG	Thomas Shrader	Downgrade	Buy→Neutral	—
Jul 1, 2025	Scotiabank	George Farmer	Downgrade	Sector Outperform→Sector Underperform	$23→$1
Feb 13, 2025	Maxim Group	Jason McCarthy	PT Raise	Buy	$22→$30
Feb 11, 2025	Scotiabank	George Farmer	PT Raise	Sector Outperform	$22→$23
Oct 21, 2024	Alliance Global Partners	James Molloy	Initiate	Buy	$20
Sep 27, 2024	Raymond James	—	Initiate	Outperform	$18
Aug 22, 2024	Scotiabank	George Farmer	Initiate	Sector Outperform	$22

Analyst Ratings News

PRO
LUCID CAPITAL MARKETS Upgrades INmune Bio to Buy, Raises Price Target to $9

LUCID CAPITAL MARKETS analyst Elemer Piros upgrades INmune Bio (NASDAQ:INMB) from Neutral to Buy and raises the price target from $2 to $9.

Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on INmune Bio, Lowers Price Target to $8

Maxim Group analyst Jason McCarthy maintains INmune Bio (NASDAQ:INMB) with a Buy and lowers the price target from $30 to $8.

Benzinga Newsdesk

This Textron Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Avi Kapoor

PRO
BTIG Downgrades INmune Bio to Neutral

BTIG analyst Thomas Shrader downgrades INmune Bio (NASDAQ:INMB) from Buy to Neutral.

Benzinga Newsdesk

PRO
Scotiabank Downgrades INmune Bio to Sector Underperform, Lowers Price Target to $0.6

Scotiabank analyst George Farmer downgrades INmune Bio (NASDAQ:INMB) from Sector Outperform to Sector Underperform and lowers the price target from $23 to $0.6.

Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on INmune Bio, Raises Price Target to $30

Maxim Group analyst Jason McCarthy maintains INmune Bio (NASDAQ:INMB) with a Buy and raises the price target from $22 to $30.

Benzinga Newsdesk